Transdermal glimepiride delivery system based on optimized ethosomal nano-vesicles: Preparation, characterization, in vitro, ex vivo and clinical evaluation
[Display omitted] This work aimed to develop an optimized ethosomal formulation of glimepiride then loading into transdermal films to offer lower drug side effect, extended release behavior and avoid first pass effect. Four formulation factors were optimized for their effects on vesicle size (Y1), e...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2016-03, Vol.500 (1-2), p.245-254 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 254 |
---|---|
container_issue | 1-2 |
container_start_page | 245 |
container_title | International journal of pharmaceutics |
container_volume | 500 |
creator | Ahmed, Tarek A. El-Say, Khalid M. Aljaeid, Bader M. Fahmy, Usama A. Abd-Allah, Fathy I. |
description | [Display omitted]
This work aimed to develop an optimized ethosomal formulation of glimepiride then loading into transdermal films to offer lower drug side effect, extended release behavior and avoid first pass effect. Four formulation factors were optimized for their effects on vesicle size (Y1), entrapment efficiency (Y2) and vesicle flexibility (Y3). Optimum desirability was identified and, an optimized formulation was prepared, characterized and loaded into transdermal films. Ex-vivo permeation study for the prepared films was conducted and, the permeation parameters and drug permeation mechanism were identified. Penetration through rat skin was studied using confocal laser microscope. In-vivo study was performed following transdermal application on human volunteers. The percent of alcohol was significantly affecting all the studied responses while the other factors and their interaction effects were varied on their effects on each response. The optimized ethosomal formulation showed observed values for Y1, Y2 and Y3 of 61nm, 97.12% and 54.03, respectively. Ex-vivo permeation of films loaded with optimized ethosomal formulation was superior to that of the corresponding pure drug transdermal films and this finding was also confirmed after confocal laser microscope study. Permeation of glimepiride from the prepared films was in favor of Higushi-diffusion model and exhibited non-Fickian or anomalous release mechanism. In-vivo study revealed extended drug release behavior and lower maximum drug plasma level from transdermal films loaded with drug ethosomal formulation. So, the ethosomal formulation could be considered a suitable drug delivery system especially when loaded into transdermal vehicle with possible reduction in side effects and controlling the drug release. |
doi_str_mv | 10.1016/j.ijpharm.2016.01.017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1765580279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517316300187</els_id><sourcerecordid>1765580279</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-72ddebd26ec23821d7aa26e295eeff9a1f70d67f0259bbe19a939d1e71da2f043</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxi0EotvCI4B85NAs_tPYGy6oqqAgVYJDOVuOPaGzSuxgeyO2z8LD4mUXrkgj2Z_1-2bG-gh5xdmaM67ebte4nR9smtaiyjXjtfQTsuIbLRt5pdVTsmJSb5qWa3lGznPeMsaU4PI5ORNK65YpuSK_7pMN2UOa7Ei_jzjBjAk9UA8jLpD2NO9zgYn2NoOnMdA4F5zwsQooDzHHgzHYEJsFMroR8jv6NcFsky0YwyV1dUnrCiR8PL1goAuWFC8p_Ky3JVIbPHUjBnS1GSx23P1BX5Bngx0zvDydF-Tbxw_3N5-auy-3n2-u7xonVVsaLbyH3gsFTsiN4F5bW4XoWoBh6CwfNPNKD0y0Xd8D72wnO89Bc2_FwK7kBXlz7Dun-GMHuZgJs4NxtAHiLhuuVdtumNBdRdsj6lLMOcFg5oSTTXvDmTkEY7bmFIw5BGMYr6Wr7_VpxK6fwP9z_U2iAu-PANSPLgjJZIcQHHhM4IrxEf8z4jcnG6bD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1765580279</pqid></control><display><type>article</type><title>Transdermal glimepiride delivery system based on optimized ethosomal nano-vesicles: Preparation, characterization, in vitro, ex vivo and clinical evaluation</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Ahmed, Tarek A. ; El-Say, Khalid M. ; Aljaeid, Bader M. ; Fahmy, Usama A. ; Abd-Allah, Fathy I.</creator><creatorcontrib>Ahmed, Tarek A. ; El-Say, Khalid M. ; Aljaeid, Bader M. ; Fahmy, Usama A. ; Abd-Allah, Fathy I.</creatorcontrib><description>[Display omitted]
This work aimed to develop an optimized ethosomal formulation of glimepiride then loading into transdermal films to offer lower drug side effect, extended release behavior and avoid first pass effect. Four formulation factors were optimized for their effects on vesicle size (Y1), entrapment efficiency (Y2) and vesicle flexibility (Y3). Optimum desirability was identified and, an optimized formulation was prepared, characterized and loaded into transdermal films. Ex-vivo permeation study for the prepared films was conducted and, the permeation parameters and drug permeation mechanism were identified. Penetration through rat skin was studied using confocal laser microscope. In-vivo study was performed following transdermal application on human volunteers. The percent of alcohol was significantly affecting all the studied responses while the other factors and their interaction effects were varied on their effects on each response. The optimized ethosomal formulation showed observed values for Y1, Y2 and Y3 of 61nm, 97.12% and 54.03, respectively. Ex-vivo permeation of films loaded with optimized ethosomal formulation was superior to that of the corresponding pure drug transdermal films and this finding was also confirmed after confocal laser microscope study. Permeation of glimepiride from the prepared films was in favor of Higushi-diffusion model and exhibited non-Fickian or anomalous release mechanism. In-vivo study revealed extended drug release behavior and lower maximum drug plasma level from transdermal films loaded with drug ethosomal formulation. So, the ethosomal formulation could be considered a suitable drug delivery system especially when loaded into transdermal vehicle with possible reduction in side effects and controlling the drug release.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2016.01.017</identifier><identifier>PMID: 26775063</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Cutaneous ; Administration, Oral ; Adult ; Animals ; Drug Compounding ; Drug Delivery Systems ; Ethosomes ; Ex-vivo permeation ; Glimepiride ; Human volunteers ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - blood ; Hypoglycemic Agents - chemistry ; Hypoglycemic Agents - pharmacokinetics ; In Vitro Techniques ; Male ; Middle Aged ; Rats, Wistar ; Skin - metabolism ; Skin Absorption ; Sulfonylurea Compounds - administration & dosage ; Sulfonylurea Compounds - blood ; Sulfonylurea Compounds - chemistry ; Sulfonylurea Compounds - pharmacokinetics ; Transdermal delivery</subject><ispartof>International journal of pharmaceutics, 2016-03, Vol.500 (1-2), p.245-254</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-72ddebd26ec23821d7aa26e295eeff9a1f70d67f0259bbe19a939d1e71da2f043</citedby><cites>FETCH-LOGICAL-c365t-72ddebd26ec23821d7aa26e295eeff9a1f70d67f0259bbe19a939d1e71da2f043</cites><orcidid>0000-0002-9247-4400</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2016.01.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26775063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahmed, Tarek A.</creatorcontrib><creatorcontrib>El-Say, Khalid M.</creatorcontrib><creatorcontrib>Aljaeid, Bader M.</creatorcontrib><creatorcontrib>Fahmy, Usama A.</creatorcontrib><creatorcontrib>Abd-Allah, Fathy I.</creatorcontrib><title>Transdermal glimepiride delivery system based on optimized ethosomal nano-vesicles: Preparation, characterization, in vitro, ex vivo and clinical evaluation</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted]
This work aimed to develop an optimized ethosomal formulation of glimepiride then loading into transdermal films to offer lower drug side effect, extended release behavior and avoid first pass effect. Four formulation factors were optimized for their effects on vesicle size (Y1), entrapment efficiency (Y2) and vesicle flexibility (Y3). Optimum desirability was identified and, an optimized formulation was prepared, characterized and loaded into transdermal films. Ex-vivo permeation study for the prepared films was conducted and, the permeation parameters and drug permeation mechanism were identified. Penetration through rat skin was studied using confocal laser microscope. In-vivo study was performed following transdermal application on human volunteers. The percent of alcohol was significantly affecting all the studied responses while the other factors and their interaction effects were varied on their effects on each response. The optimized ethosomal formulation showed observed values for Y1, Y2 and Y3 of 61nm, 97.12% and 54.03, respectively. Ex-vivo permeation of films loaded with optimized ethosomal formulation was superior to that of the corresponding pure drug transdermal films and this finding was also confirmed after confocal laser microscope study. Permeation of glimepiride from the prepared films was in favor of Higushi-diffusion model and exhibited non-Fickian or anomalous release mechanism. In-vivo study revealed extended drug release behavior and lower maximum drug plasma level from transdermal films loaded with drug ethosomal formulation. So, the ethosomal formulation could be considered a suitable drug delivery system especially when loaded into transdermal vehicle with possible reduction in side effects and controlling the drug release.</description><subject>Administration, Cutaneous</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>Animals</subject><subject>Drug Compounding</subject><subject>Drug Delivery Systems</subject><subject>Ethosomes</subject><subject>Ex-vivo permeation</subject><subject>Glimepiride</subject><subject>Human volunteers</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - blood</subject><subject>Hypoglycemic Agents - chemistry</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Rats, Wistar</subject><subject>Skin - metabolism</subject><subject>Skin Absorption</subject><subject>Sulfonylurea Compounds - administration & dosage</subject><subject>Sulfonylurea Compounds - blood</subject><subject>Sulfonylurea Compounds - chemistry</subject><subject>Sulfonylurea Compounds - pharmacokinetics</subject><subject>Transdermal delivery</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9u1DAQxi0EotvCI4B85NAs_tPYGy6oqqAgVYJDOVuOPaGzSuxgeyO2z8LD4mUXrkgj2Z_1-2bG-gh5xdmaM67ebte4nR9smtaiyjXjtfQTsuIbLRt5pdVTsmJSb5qWa3lGznPeMsaU4PI5ORNK65YpuSK_7pMN2UOa7Ei_jzjBjAk9UA8jLpD2NO9zgYn2NoOnMdA4F5zwsQooDzHHgzHYEJsFMroR8jv6NcFsky0YwyV1dUnrCiR8PL1goAuWFC8p_Ky3JVIbPHUjBnS1GSx23P1BX5Bngx0zvDydF-Tbxw_3N5-auy-3n2-u7xonVVsaLbyH3gsFTsiN4F5bW4XoWoBh6CwfNPNKD0y0Xd8D72wnO89Bc2_FwK7kBXlz7Dun-GMHuZgJs4NxtAHiLhuuVdtumNBdRdsj6lLMOcFg5oSTTXvDmTkEY7bmFIw5BGMYr6Wr7_VpxK6fwP9z_U2iAu-PANSPLgjJZIcQHHhM4IrxEf8z4jcnG6bD</recordid><startdate>20160316</startdate><enddate>20160316</enddate><creator>Ahmed, Tarek A.</creator><creator>El-Say, Khalid M.</creator><creator>Aljaeid, Bader M.</creator><creator>Fahmy, Usama A.</creator><creator>Abd-Allah, Fathy I.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9247-4400</orcidid></search><sort><creationdate>20160316</creationdate><title>Transdermal glimepiride delivery system based on optimized ethosomal nano-vesicles: Preparation, characterization, in vitro, ex vivo and clinical evaluation</title><author>Ahmed, Tarek A. ; El-Say, Khalid M. ; Aljaeid, Bader M. ; Fahmy, Usama A. ; Abd-Allah, Fathy I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-72ddebd26ec23821d7aa26e295eeff9a1f70d67f0259bbe19a939d1e71da2f043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Administration, Cutaneous</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>Animals</topic><topic>Drug Compounding</topic><topic>Drug Delivery Systems</topic><topic>Ethosomes</topic><topic>Ex-vivo permeation</topic><topic>Glimepiride</topic><topic>Human volunteers</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - blood</topic><topic>Hypoglycemic Agents - chemistry</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Rats, Wistar</topic><topic>Skin - metabolism</topic><topic>Skin Absorption</topic><topic>Sulfonylurea Compounds - administration & dosage</topic><topic>Sulfonylurea Compounds - blood</topic><topic>Sulfonylurea Compounds - chemistry</topic><topic>Sulfonylurea Compounds - pharmacokinetics</topic><topic>Transdermal delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmed, Tarek A.</creatorcontrib><creatorcontrib>El-Say, Khalid M.</creatorcontrib><creatorcontrib>Aljaeid, Bader M.</creatorcontrib><creatorcontrib>Fahmy, Usama A.</creatorcontrib><creatorcontrib>Abd-Allah, Fathy I.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmed, Tarek A.</au><au>El-Say, Khalid M.</au><au>Aljaeid, Bader M.</au><au>Fahmy, Usama A.</au><au>Abd-Allah, Fathy I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transdermal glimepiride delivery system based on optimized ethosomal nano-vesicles: Preparation, characterization, in vitro, ex vivo and clinical evaluation</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2016-03-16</date><risdate>2016</risdate><volume>500</volume><issue>1-2</issue><spage>245</spage><epage>254</epage><pages>245-254</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted]
This work aimed to develop an optimized ethosomal formulation of glimepiride then loading into transdermal films to offer lower drug side effect, extended release behavior and avoid first pass effect. Four formulation factors were optimized for their effects on vesicle size (Y1), entrapment efficiency (Y2) and vesicle flexibility (Y3). Optimum desirability was identified and, an optimized formulation was prepared, characterized and loaded into transdermal films. Ex-vivo permeation study for the prepared films was conducted and, the permeation parameters and drug permeation mechanism were identified. Penetration through rat skin was studied using confocal laser microscope. In-vivo study was performed following transdermal application on human volunteers. The percent of alcohol was significantly affecting all the studied responses while the other factors and their interaction effects were varied on their effects on each response. The optimized ethosomal formulation showed observed values for Y1, Y2 and Y3 of 61nm, 97.12% and 54.03, respectively. Ex-vivo permeation of films loaded with optimized ethosomal formulation was superior to that of the corresponding pure drug transdermal films and this finding was also confirmed after confocal laser microscope study. Permeation of glimepiride from the prepared films was in favor of Higushi-diffusion model and exhibited non-Fickian or anomalous release mechanism. In-vivo study revealed extended drug release behavior and lower maximum drug plasma level from transdermal films loaded with drug ethosomal formulation. So, the ethosomal formulation could be considered a suitable drug delivery system especially when loaded into transdermal vehicle with possible reduction in side effects and controlling the drug release.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26775063</pmid><doi>10.1016/j.ijpharm.2016.01.017</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-9247-4400</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-5173 |
ispartof | International journal of pharmaceutics, 2016-03, Vol.500 (1-2), p.245-254 |
issn | 0378-5173 1873-3476 |
language | eng |
recordid | cdi_proquest_miscellaneous_1765580279 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Administration, Cutaneous Administration, Oral Adult Animals Drug Compounding Drug Delivery Systems Ethosomes Ex-vivo permeation Glimepiride Human volunteers Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - blood Hypoglycemic Agents - chemistry Hypoglycemic Agents - pharmacokinetics In Vitro Techniques Male Middle Aged Rats, Wistar Skin - metabolism Skin Absorption Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - blood Sulfonylurea Compounds - chemistry Sulfonylurea Compounds - pharmacokinetics Transdermal delivery |
title | Transdermal glimepiride delivery system based on optimized ethosomal nano-vesicles: Preparation, characterization, in vitro, ex vivo and clinical evaluation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T00%3A48%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transdermal%20glimepiride%20delivery%20system%20based%20on%20optimized%20ethosomal%20nano-vesicles:%20Preparation,%20characterization,%20in%20vitro,%20ex%20vivo%20and%20clinical%20evaluation&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Ahmed,%20Tarek%20A.&rft.date=2016-03-16&rft.volume=500&rft.issue=1-2&rft.spage=245&rft.epage=254&rft.pages=245-254&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2016.01.017&rft_dat=%3Cproquest_cross%3E1765580279%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1765580279&rft_id=info:pmid/26775063&rft_els_id=S0378517316300187&rfr_iscdi=true |